Navigation Links
Molecular Basis Of ALS Found

Northwestern University researchers have discovered the molecular basis of the neurodegenerative disease amyotrophic lateral sclerosis (ALS).// Two separate teams including neurologists and biochemists worked on how the mutated form of superoxide dismutase (SOD1) protein renders people vulnerable to formation of intermolecular aggregates. This mutated protein is associated with a familial form of ALS.

The findings, which have implications for new therapeutics for the devastating disease, were published online this week in two related papers by the Proceedings of the National Academy of Sciences (PNAS).

ALS is a progressive paralytic disorder caused by degeneration of motor neurons in the brain and spinal cord. The cause and development (pathogenesis) of the fatal disease are not known, and there is no effective treatment. Fifteen years ago, an international consortium led by Teepu Siddique, M.D., Les Turner ALS Foundation/Herbert C. Wenske Foundation Professor at Northwestern's Feinberg School of Medicine, mapped the first ALS gene to chromosome 21. Subsequently, they found that mutations in the SOD1 gene are responsible for 20 percent of familial (inherited) ALS cases. Siddique and his colleagues also made the first ALS transgenic mouse models.

Although more than 100 types of a single mutation in the SOD1 gene have been identified and multiple lines of the mouse models developed, a key question remains to be answered: How does the genetic mutation alter this incredibly stable protein to make it so toxic that it kills motor neurons and causes neurodegenerative disease? The presence of aggregated proteins is common to many neurodegenerative disorders, including ALS and Alzheimer's, Parkinson's and prion diseases, but the relevance of these aggregates to the diseases is not well understood. In ALS patients with SOD1 mutations and mouse models overexpressing mutant SOD1, SOD1-positive aggregates were identified in neurons. Researchers do not know if these aggregates are causative, harmless or even beneficial to ALS. Furthermore, the fundamental molecular mechanism by which the SOD1 mutants form aggregates is not clear.

Six years ago Siddique and Han-Xiang Deng, M.D., associate professor of neurology at the Feinberg School, started to develop and analyze various SOD1 transgenic mouse models and found, as they report in the first of the two PNAS papers, that aggregated and insoluble SOD1 is the pathogenic form that causes disease. The aggregation takes place in mitochondria, the powerhouse of the cell, which becomes damaged.

"We also have discovered a mechanism whereby 'normal' molecules of SOD1 are recruited in the presence of mutant SOD1 proteins to participate in the pathogenesis of ALS by forming intermolecular disulfide bonds," said Siddique. "This phenomenon is in some ways akin to the recruitment noted in prion disorders and provides molecular sites for therapeutic intervention." This molecular mechanism also may help explain other types of ALS in which no mutations have been detected in SOD1.

The normal form of SOD1 is a molecule composed of two identical parts, each with an amino acid chain, a copper ion, a zinc ion and an intramolecular disulfide linkage -- a bond within an SOD1 molecule that stabilizes the structure. Intermolecular disulfide bonds, or cross-links, are incorrect bonds that form between, not within, SOD1 molecules.

"A year ago we demonstrated that ALS mutations have the greatest effect on the most immature form of the SOD1 protein, causing it to misfold and form incorrect disulfide bonds that facilitate protein aggregation," said Thomas V. O'Halloran, professor of chemistry. "Those were test tube experiments, but we really wanted to know if we would find the same process in a physiological environment." To investigate their hypothesis further, O'Halloran and Yoshiaki Furukawa, formerly a post-doctoral fellow in O'Halloran's lab, team ed up with Siddique and Deng. As reported in the second PNAS paper, they show that increased oxidative stress leads to the mutant SOD1 protein forming incorrect disulfide bonds early in its life. The researchers isolated and examined aggregates from the spinal cord of several ALS-model mice. In the diseased mice the scientists found intermolecular disulfide bonds that cross-linked SOD1 molecules together, resulting in the formation of insoluble aggregates. The SOD1 aggregates were specific to the spinal cord, the part of the body most damaged in ALS. Tissues unaffected by the disease, such as the brain and liver, had no aggregates.

Oxidation and protein aggregation have been suspected to play an important role in the pathogenesis of neurodegenerative disorders as well as in the normal aging process. However, the relationship between protein oxidation, protein aggregation and neurodegeneration remains unclear. The oxidative intermolecular disulfide cross-linking paradigm established by the Northwestern researchers provides direct links between protein oxidation, protein aggregation and neurodegeneration in SOD1-mediated ALS. This mechanism may play an important role not only in SOD1-mediated ALS but also in some other neurodegenerative disorders.

"For some time researchers have been thinking that copper, which causes the protein to be bluish-green in color, was the bad guy in this disease," said O'Halloran. "But the data has been building up to say that something else may be responsible for the toxicity. Our results suggest that the status of the disulfide bond, a long overlooked part of the SOD1 protein, plays a pivotal role. The ALS mutations appear to predispose SOD1 to form incorrect disulfide bonds that lead to aggregation of the protein and perhaps initiation of the disease. If these ideas are borne out, our next step is to look for therapeutic approaches that could prevent formation of the disulfide cross-linked aggregates." Source: Eur ekalert
'"/>




Related medicine news :

1. Molecular markers for early diagnosis of breast and ovarian cancer
2. Scientists Developed Map For Brain Molecular Communities
3. Molecular Mechanism Of HIV Infecting The Healthy Cells Discovered.
4. Molecular Flaw Detected in Aggressive Breast Cancers
5. Molecular Computer Developed To perform Calculations From Within Human Body
6. Molecular Imaging Of Cancer Now Possible, New Hybrid Virus Produced
7. New Molecular Treatment Identified To Treat Blood Cell Cancers
8. Researchers Find Molecular "Brake" to Cell Death
9. Solitons Could Power Molecular Electronics, Artificial Muscles
10. Discovery of Agile Molecular Motors Could Aid in Treating Motor Neuron Diseases
11. Joint Center for Molecular Modeling Instituted by Burnham Institute for Medical Research & UC San Diego
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2016)... ... December 06, 2016 , ... Individuals who seek to ... as drinking more water or limiting their exposure to the sun, according to a ... beauty group Beverly Hills Physicians (BHP) notes that, while preventive measures to help keep ...
(Date:12/6/2016)... ... December 06, 2016 , ... An inventor, from Talladega, Ala., thought there ... she invented the patent-pending SLING-VEST. , The SLING-VEST provides an effective way to support ... to traditional slings. As a result, it helps to reduce discomfort and shifting. The ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... health insights for population health management, announces today a strategic relationship with ... CitiusTech’s cloud-hosted clinical rules engine that offers advanced Clinical Quality Measures (CQM) ...
(Date:12/6/2016)... ... December 06, 2016 , ... It ... Women’s Magazine inaugural Maine Women’s Expo. Hundreds of women gathered to check out ... resource. The expo’s beneficiary this year was Crossroads, a fully-accredited gender-responsive treatment ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Touchpoint Solution’s new ... after launch. Almost 200 backers pledged more than $25,000 on Kickstarter ... , Dr. Amy Serin, an Arizona Neuropsychologist and inventor, says she feels like ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016 /PRNewswire/ ... leading RNA medicines company, announced today that it ... to develop RNA-based therapeutics for the treatment of ... Arcturus, wholly-owned therapeutic delivery platform LUNAR™ and UNA ... "Given Takeda,s long-standing commitment to and ...
(Date:12/6/2016)... 6, 2016  Regulus Therapeutics Inc. (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, ... its R&D day, held in New ... an anti-miR targeting microRNA-27 (miR-27) for the treatment ... an anti-miR targeting microRNA-17 (miR-17) for the treatment ...
(Date:12/6/2016)... , Dec. 6, 2016 A new study ... 340B (AIR 340B) projects the 340B Drug Pricing Program will ... which time it is expected to exceed $23 billion in ... see 340B purchases surpass current Medicare Part B drug reimbursement ... new study – based on analysis of data on total ...
Breaking Medicine Technology: